Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review
Open accessThe DOI matches its Crossref record; 272 of the 272 references it cites were found in a registry or an index.
Abstract
Breast cancer (BC) is the most frequently diagnosed cancer in women worldwide with more than 2 million new cases in 2020. Its incidence and death rates have increased over the last three decades due to the change in risk factor profiles, better cancer registration, and cancer detection. The number of risk factors of BC is significant and includes both the modifiable factors and non-modifiable factors. Currently, about 80% of patients with BC are individuals aged >50. Survival depends on both stage and molecular subtype. Invasive BCs comprise wide spectrum tumors that show a variation concerning their clinical presentation, behavior, and morphology. Based on mRNA gene expression levels, BC can be divided into molecular subtypes (Luminal A, Luminal B, HER2-enriched, and basal-like). The molecular subtypes provide insights into new treatment strategies and patient stratifications that impact the management of BC patients. The eighth edition of TNM classification outlines a new staging system for BC that, in addition to anatomical features, acknowledges biological factors. Treatment of breast cancer is complex and involves a combination of different modalities including surgery, radiotherapy, chemotherapy, hormonal therapy, or biological therapies delivered in diverse sequences.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Hsa-miR-139-5p inhibits proliferation and causes apoptosis associated with down-regulation of c-Met
Sun, C., Sang, M., Li, S., Sun, X., Yang, C., Xi, Y., Wang, L., Zhang, F., Bi, Y., Fu, Y., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5476 · Cited by 116
RetractedSung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Correspondence - Tranexamic acid for traumatic brain injury
(2005) · London School of Economics and Political Science Theses Online (London School of Economics and Political Science) · doi:10.1016/s0140-6736 · Cited by 11,894
Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21208 · Cited by 11,499
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399 · cited 1×
“As lymphocytes have an antitumor activity by inducing cytotoxic cell death and inhibiting tumor proliferation [270], the monocytes are involved in tumorigenesis, including differentiation into TAMs [246,247,271].”
BackgroundSørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
ELSTON, C. W., & ELLIS, I. O. (1991) · Histopathology · doi:10.1111/j.1365-2559.1991.tb00229.x · Cited by 6,175
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
MANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528 · cited 1×
“Macrophages are known for their immunomodulatory effects and they can be divided according to their phenotypes into M1- or M2-like states [244,245].”
BackgroundSupervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,721
Hammond, M. E. H., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., Fitzgibbons, P. L., Francis, G., Goldstein, N. S., Hayes, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.6529 · Cited by 4,213
Alternative activation of macrophages: mechanism and functions
Gordon, S., & Martinez, F. O. (2010) · Immunity · doi:10.1016/j.immuni.2010.05.007 · Cited by 4,197 · cited 1×
“Macrophages are known for their immunomodulatory effects and they can be divided according to their phenotypes into M1- or M2-like states [244,245].”
BackgroundWolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.9984 · Cited by 4,030
Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
Carey, L. A., Perou, C. M., Livasy, C. A., Dressler, L. G., Cowan, D., Conway, K., Karaca, G., Troester, M. A., Tse, C. K., Edmiston, S., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2492 · Cited by 3,819
Goldhirsch, A., Winer, E. P., Coates, A. S., Gelber, R. D., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J., Albain, K. S., André, F., Bergh, J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt303 · Cited by 3,746
Bloom, H. J. G., & Richardson, W. W. (1957) · British Journal of Cancer · doi:10.1038/bjc.1957.43 · Cited by 2,925
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S., Davidson, T., Gruber, G., & Castiglione, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq159 · Cited by 2,842
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
Cheang, M. C. U., Chia, S. K., Voduc, D., Gao, D., Leung, S., Snider, J., Watson, M., Davies, S., Bernard, P. S., Parker, J. S., et al. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp082 · Cited by 2,249
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I. T., Zackrisson, S., & Senkus, E. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz173 · Cited by 2,214
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
Prat, A., Parker, J. S., Karginova, O., Fan, C., Livasy, C., Herschkowitz, J. I., He, X., & Perou, C. M. (2010) · Breast Cancer Research · doi:10.1186/bcr2635 · Cited by 2,167
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
Fisher, B., Bryant, J., Wolmark, N., Mamounas, E., Brown, A., Fisher, E. R., Wickerham, D. L., Begovic, M., DeCillis, A., Robidoux, A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2672 · Cited by 2,165
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
Rouzier, R., Perou, C. M., Symmans, W. F., Ibrahim, N., Cristofanilli, M., Anderson, K., Hess, K. R., Stec, J., Ayers, M., Wagner, P., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2421 · Cited by 1,891
The Endogenous Hormones and Breast Cancer Collaborative Group (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.8.606 · Cited by 1,793
MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review
Iorio, M. V., & Croce, C. M. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201100209 · Cited by 1,739
The systemic inflammation-based neutrophil–lymphocyte ratio: Experience in patients with cancer
Guthrie, G. J. K., Charles, K. A., Roxburgh, C. S. D., Horgan, P. G., McMillan, D. C., & Clarke, S. J. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.03.010 · Cited by 1,552
US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
Howlader, N., Altekruse, S. F., Li, C. I., Chen, V. W., Clarke, C. A., Ries, L. A. G., & Cronin, K. A. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju055 · Cited by 1,508
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E., Dees, E. C., Perez, E. A., Olson, J. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510764 · Cited by 1,388
Iqbal, N., & Iqbal, N. (2014) · Molecular Biology International · doi:10.1155/2014/852748 · Cited by 1,381
Deconstructing the molecular portraits of breast cancer
Prat, A., & Perou, C. M. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2010.11.003 · Cited by 1,343
Clinical Implications of the p53 Tumor-Suppressor Gene
Harris, C. C., & Hollstein, M. (1993) · New England Journal of Medicine · doi:10.1056/nejm199310283291807 · Cited by 1,330
Clinical implications of the intrinsic molecular subtypes of breast cancer
Prat, A., Pineda, E., Adamo, B., Galván, P., Fernández, A., Gaba, L., Díez, M., Viladot, M., Arance, A., & Muñoz, M. (2015) · The Breast · doi:10.1016/j.breast.2015.07.008 · Cited by 1,319
Herschkowitz, J. I., Simin, K., Weigman, V. J., Mikaelian, I., Usary, J., Hu, Z., Rasmussen, K. E., Jones, L. P., Assefnia, S., Chandrasekharan, S., et al. (2007) · Genome Biology · doi:10.1186/gb-2007-8-5-r76 · Cited by 1,285
Kyu, H. H., Bachman, V. F., Alexander, L. T., Mumford, J. E., Afshin, A., Estep, K., Veerman, J. L., Delwiche, K., Iannarone, M. L., Moyer, M. L., et al. (2016) · BMJ · doi:10.1136/bmj.i3857 · Cited by 1,272
Breast cancer statistics, 2015: Convergence of incidence rates between black and white women
DeSantis, C. E., Fedewa, S. A., Goding Sauer, A., Kramer, J. L., Smith, R. A., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21320 · Cited by 1,252
Cheang, M. C. U., Voduc, D., Bajdik, C., Leung, S., McKinney, S., Chia, S. K., Perou, C. M., & Nielsen, T. O. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1658 · Cited by 1,195
An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers
Roberts, S. A., Lawrence, M. S., Klimczak, L. J., Grimm, S. A., Fargo, D., Stojanov, P., Kiezun, A., Kryukov, G. V., Carter, S. L., Saksena, G., et al. (2013) · Nature Genetics · doi:10.1038/ng.2702 · Cited by 1,167
The global burden of women's cancers: a grand challenge in global health
Ginsburg, O., Bray, F., Coleman, M. P., Vanderpuye, V., Eniu, A., Kotha, S. R., Sarker, M., Huong, T. T., Allemani, C., Dvaladze, A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31392-7 · Cited by 1,127
The CHEK2-Breast Cancer Consortium (2002) · Nature Genetics · doi:10.1038/ng879 · Cited by 1,104
Cancer Incidence in BRCA1 Mutation Carriers
Thompson, D. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.18.1358 · Cited by 1,096
Fiolet, T., Srour, B., Sellem, L., Kesse-Guyot, E., Allès, B., Méjean, C., Deschasaux, M., Fassier, P., Latino-Martel, P., Beslay, M., et al. (2018) · BMJ · doi:10.1136/bmj.k322 · Cited by 1,057
PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene
The Breast Cancer Susceptibility Collaboration (UK), Rahman, N., Seal, S., Thompson, D., Kelly, P., Renwick, A., Elliott, A., Reid, S., Spanova, K., Barfoot, R., et al. (2007) · Nature Genetics · doi:10.1038/ng1959 · Cited by 1,003
Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis
Protani, M., Coory, M., & Martin, J. H. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0990-0 · Cited by 962
de Azambuja, E., Cardoso, F., de Castro, G., Colozza, M., Mano, M. S., Durbecq, V, Sotiriou, C., Larsimont, D., Piccart-Gebhart, M. J., & Paesmans, M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603756 · Cited by 959
Bartelink, H., Horiot, J.-C., Poortmans, P., Struikmans, H., Van den Bogaert, W., Barillot, I., Fourquet, A., Borger, J., Jager, J., Hoogenraad, W., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010874 · Cited by 941
Benign Breast Disease and the Risk of Breast Cancer
Hartmann, L. C., Sellers, T. A., Frost, M. H., Lingle, W. L., Degnim, A. C., Ghosh, K., Vierkant, R. A., Maloney, S. D., Pankratz, V. S., Hillman, D. W., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044383 · Cited by 938
Kohler, B. A., Sherman, R. L., Howlader, N., Jemal, A., Ryerson, A. B., Henry, K. A., Boscoe, F. P., Cronin, K. A., Lake, A., Noone, A.-M., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv048 · Cited by 915
TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes
Petitjean, A., Achatz, M. I. W., Borresen-Dale, A. L., Hainaut, P., & Olivier, M. (2007) · Oncogene · doi:10.1038/sj.onc.1210302 · Cited by 884 · cited 1×
“There have been many studies showing the prognostic role of p53 loss-of-function mutation in breast cancer [227,228].”
BackgroundHennessy, B. T., Gonzalez-Angulo, A.-M., Stemke-Hale, K., Gilcrease, M. Z., Krishnamurthy, S., Lee, J.-S., Fridlyand, J., Sahin, A., Agarwal, R., Joy, C., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3441 · Cited by 874
p53 in the DNA–Damage–Repair Process
Williams, A. B., & Schumacher, B. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026070 · Cited by 835 · cited 1×
“P53 protein is essential for normal cellular homeostasis and genome maintenance by mediating cellular stress responses including cell cycle arrest, apoptosis, DNA repair, and cellular senescence [225].”
BackgroundProctor, M. J., Morrison, D. S., Talwar, D., Balmer, S. M., Fletcher, C. D., O’Reilly, D. S. J., Foulis, A. K., Horgan, P. G., & McMillan, D. C. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.03.028 · Cited by 757
The Breast Cancer Susceptibility Collaboration (UK), Seal, S., Thompson, D., Renwick, A., Elliott, A., Kelly, P., Barfoot, R., Chagtai, T., Jayatilake, H., Ahmed, M., et al. (2006) · Nature Genetics · doi:10.1038/ng1902 · Cited by 746
ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles
The Breast Cancer Susceptibility Collaboration (UK), Renwick, A., Thompson, D., Seal, S., Kelly, P., Chagtai, T., Ahmed, M., North, B., Jayatilake, H., Barfoot, R., et al. (2006) · Nature Genetics · doi:10.1038/ng1837 · Cited by 743
Endogenous Hormones and Breast Cancer Risk
Bernstein, L., & Ross, R. K. (1993) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a036116 · Cited by 691
Role of platelets and platelet receptors in cancer metastasis
Schlesinger, M. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0669-2 · Cited by 690
Badve, S., Dabbs, D. J., Schnitt, S. J., Baehner, F. L., Decker, T., Eusebi, V., Fox, S. B., Ichihara, S., Jacquemier, J., Lakhani, S. R., et al. (2011) · Modern Pathology · doi:10.1038/modpathol.2010.200 · Cited by 680
Medrek, C., Pontén, F., Jirström, K., & Leandersson, K. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-306 · Cited by 647
Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways
Eroles, P., Bosch, A., Alejandro Pérez-Fidalgo, J., & Lluch, A. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.11.005 · Cited by 624
Cancer survival in Africa, Asia, and Central America: a population-based study
Sankaranarayanan, R., Swaminathan, R., Brenner, H., Chen, K., Chia, K. S., Chen, J. G., Law, S. C., Ahn, Y.-O., Xiang, Y. B., Yeole, B. B., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70335-3 · Cited by 616
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.
Olivier, M., Langer√∏d, A., Carrieri, P., Bergh, J., Klaar, S., Eyfjord, J., Theillet, C., Rodriguez, C., Lidereau, R., Bi√®che, I., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1029 · Cited by 589
Prat, A., Cheang, M. C. U., Martín, M., Parker, J. S., Carrasco, E., Caballero, R., Tyldesley, S., Gelmon, K., Bernard, P. S., Nielsen, T. O., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.4134 · Cited by 587
Diversity of Breast Carcinoma: Histological Subtypes and Clinical Relevance
Makki, J. (2015) · Clinical Medicine Insights: Pathology · doi:10.4137/cpath.s31563 · Cited by 583
Monocyte heterogeneity and functions in cancer
Olingy, C. E., Dinh, H. Q., & Hedrick, C. C. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.4ri0818-311r · Cited by 579
Histological types of breast cancer: How special are they?
Weigelt, B., Geyer, F. C., & Reis-Filho, J. S. (2010) · Molecular Oncology · doi:10.1016/j.molonc.2010.04.004 · Cited by 572
Physical activity and the risk of breast cancer
Thune, I., Brenn, T., Lund, E., & Gaard, M. (1997) · New England Journal of Medicine · doi:10.1056/nejm199705013361801 · Cited by 569
Weigelt, B., Horlings, H., Kreike, B., Hayes, M., Hauptmann, M., Wessels, L., de Jong, D., Van de Vijver, M., Veer, L. V., & Peterse, J. (2008) · The Journal of Pathology · doi:10.1002/path.2407 · Cited by 562
“Westernizing” Women's Risks? Breast Cancer in Lower-Income Countries
Porter, P. (2008) · New England Journal of Medicine · doi:10.1056/nejmp0708307 · Cited by 558
Tumor-associated macrophages: Functional diversity, clinical significance, and open questions
Biswas, S. K., Allavena, P., & Mantovani, A. (2013) · Seminars in Immunopathology · doi:10.1007/s00281-013-0367-7 · Cited by 551
Zhang, M., He, Y., Sun, X., Li, Q., Wang, W., Zhao, A., & Di, W. (2014) · Journal of Ovarian Research · doi:10.1186/1757-2215-7-19 · Cited by 528
Genetics of breast cancer: a topic in evolution
Shiovitz, S., & Korde, L. A. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv022 · Cited by 525
Duffy, M. J., Harbeck, N., Nap, M., Molina, R., Nicolini, A., Senkus, E., & Cardoso, F. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.017 · Cited by 522
Health and Racial Disparity in Breast Cancer
Yedjou, C. G., Sims, J. N., Miele, L., Noubissi, F., Lowe, L., Fonseca, D. D., Alo, R. A., Payton, M., & Tchounwou, P. B. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-20301-6_3 · Cited by 509
Weigelt, B., Baehner, F. L., & Reis‐Filho, J. S. (2010) · The Journal of Pathology · doi:10.1002/path.2648 · Cited by 482
Adaptive Randomization of Neratinib in Early Breast Cancer
Park, J. W., Liu, M. C., Yee, D., Yau, C., van ’t Veer, L. J., Symmans, W. F., Paoloni, M., Perlmutter, J., Hylton, N. M., Hogarth, M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1513750 · Cited by 454
Adverse Health Outcomes in Women Exposed In Utero to Diethylstilbestrol
Hoover, R. N., Hyer, M., Pfeiffer, R. M., Adam, E., Bond, B., Cheville, A. L., Colton, T., Hartge, P., Hatch, E. E., Herbst, A. L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013961 · Cited by 444
Tumor-associated macrophages: unwitting accomplices in breast cancer malignancy
Williams, C. B., Yeh, E. S., & Soloff, A. C. (2016) · npj Breast Cancer · doi:10.1038/npjbcancer.2015.25 · Cited by 444
Rodgers, K. M., Udesky, J. O., Rudel, R. A., & Brody, J. G. (2018) · Environmental Research · doi:10.1016/j.envres.2017.08.045 · Cited by 443
Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives
Ades, F., Zardavas, D., Bozovic-Spasojevic, I., Pugliano, L., Fumagalli, D., de Azambuja, E., Viale, G., Sotiriou, C., & Piccart, M. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.1870 · Cited by 435
Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study
O'Brien, K. M., Cole, S. R., Tse, C.-K., Perou, C. M., Carey, L. A., Foulkes, W. D., Dressler, L. G., Geradts, J., & Millikan, R. C. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1533 · Cited by 429
The Relationship of Mammographic Density and Age: Implications for Breast Cancer Screening
Checka, C. M., Chun, J. E., Schnabel, F. R., Lee, J., & Toth, H. (2012) · American Journal of Roentgenology · doi:10.2214/ajr.10.6049 · Cited by 422
Epidemiology of Endocrine-Related Risk Factors for Breast Cancer
Bernstein, L. (2002) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1015714305420 · Cited by 401
(2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70301-2 · Cited by 399 · cited 1×
“Circulating estrogens and androgens are positively associated with an increased risk of breast cancer [14].”
BackgroundGiordano, S. H. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1707939 · Cited by 390
Mandaliya, H., Jones, M., Oldmeadow, C., & Nordman, I. I. C. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.11.16 · Cited by 384
Effects of Age on the Detection and Management of Breast Cancer
McGuire, A., Brown, J., Malone, C., McLaughlin, R., & Kerin, M. (2015) · Cancers · doi:10.3390/cancers7020815 · Cited by 374
Cigarette smoking and the risk of breast cancer in women: a review of the literature.
Terry, P., & Rohan, T. E. (2002) · PubMed · Cited by 361
Børresen-Dale, A.-L. (2003) · Human Mutation · doi:10.1002/humu.10174 · Cited by 354
Factors Predicting the Use of Breast-Conserving Therapy in Stage I and II Breast Carcinoma
Morrow, M., White, J., Moughan, J., Owen, J., Pajack, T., Sylvester, J., Frank Wilson, J., & Winchester, D. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2254 · Cited by 353
Prenatal Diethylstilbestrol Exposure and Risk of Breast Cancer
Palmer, J. R., Wise, L. A., Hatch, E. E., Troisi, R., Titus-Ernstoff, L., Strohsnitter, W., Kaufman, R., Herbst, A. L., Noller, K. L., Hyer, M., et al. (2006) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-0109 · Cited by 347
Albrektsen, G., Heuch, I., Hansen, S., & Kvåle, G. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602302 · Cited by 345
Zhao, X., Qu, J., Sun, Y., Wang, J., Liu, X., Wang, F., Zhang, H., Wang, W., Ma, X., Gao, X., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15736 · Cited by 345
The role of microRNAs in cancer: No small matter
Wiemer, E. A. C. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.04.002 · Cited by 342
Parise, C. A., Bauer, K. R., Brown, M. M., & Caggiano, V. (2009) · The Breast Journal · doi:10.1111/j.1524-4741.2009.00822.x · Cited by 331
Koh, C.-H., Bhoo-Pathy, N., Ng, K.-L., Jabir, R. S., Tan, G.-H., See, M.-H., Jamaris, S., & Taib, N. A. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.183 · Cited by 327
Family history and risk of breast cancer: an analysis accounting for family structure
Brewer, H. R., Jones, M. E., Schoemaker, M. J., Ashworth, A., & Swerdlow, A. J. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4325-2 · Cited by 316
Herrera, M., Herrera, A., Domínguez, G., Silva, J., García, V., García, J. M., Gómez, I., Soldevilla, B., Muñoz, C., Provencio, M., et al. (2013) · Cancer Science · doi:10.1111/cas.12096 · Cited by 289
Follow-up study of twenty-four families with Li-Fraumeni syndrome.
Garber, J. E., Goldstein, A. M., Kantor, A. F., Dreyfus, M., Fraumeni, J. F., & Li, F. P. (1991) · PubMed · Cited by 275
Circulating microRNAs as Specific Biomarkers for Breast Cancer Detection
Ng, E. K. O., Li, R., Shin, V. Y., Jin, H. C., Leung, C. P. H., Ma, E. S. K., Pang, R., Chua, D., Chu, K.-M., Law, W. L., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053141 · Cited by 263
Molecular classification of breast cancer
Vuong, D., Simpson, P. T., Green, B., Cummings, M. C., & Lakhani, S. R. (2014) · Virchows Archiv · doi:10.1007/s00428-014-1593-7 · Cited by 262
Vinogradova, Y., Coupland, C., & Hippisley-Cox, J. (2020) · BMJ · doi:10.1136/bmj.m3873 · Cited by 250
Azab, B., Shah, N., Radbel, J., Tan, P., Bhatt, V., Vonfrolio, S., Habeshy, A., Picon, A., & Bloom, S. (2013) · Medical Oncology · doi:10.1007/s12032-012-0432-4 · Cited by 249
Sestak, I., Cuzick, J., Dowsett, M., Lopez-Knowles, E., Filipits, M., Dubsky, P., Cowens, J. W., Ferree, S., Schaper, C., Fesl, C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.6894 · Cited by 249
Impact of aging on the biology of breast cancer
Benz, C. C. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.09.001 · Cited by 245
Do Calcium Channel Blockers Increase the Risk of Cancer?
Pahor, M. (1996) · American Journal of Hypertension · doi:10.1016/0895-7061(96)00186-0 · Cited by 242
Smoking and risk of breast cancer in the Generations Study cohort
Jones, M. E., Schoemaker, M. J., Wright, L. B., Ashworth, A., & Swerdlow, A. J. (2017) · Breast Cancer Research · doi:10.1186/s13058-017-0908-4 · Cited by 238
Mutant p53 in breast cancer: potential as a therapeutic target and biomarker
Duffy, M. J., Synnott, N. C., & Crown, J. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4753-7 · Cited by 235
Prat, A., Carey, L. A., Adamo, B., Vidal, M., Tabernero, J., Cortés, J., Parker, J. S., Perou, C. M., & Baselga, J. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju152 · Cited by 233
Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial
Bjarnadottir, O., Romero, Q., Bendahl, P.-O., Jirström, K., Rydén, L., Loman, N., Uhlén, M., Johannesson, H., Rose, C., Grabau, D., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2473-6 · Cited by 230
The validity of the mortality to incidence ratio as a proxy for site-specific cancer survival
Asadzadeh Vostakolaei, F., Karim-Kos, H. E., Janssen-Heijnen, M. L. G., Visser, O., Verbeek, A. L. M., & Kiemeney, L. A. L. M. (2011) · European Journal of Public Health · doi:10.1093/eurpub/ckq120 · Cited by 230
Weiss, A., Chavez-MacGregor, M., Lichtensztajn, D. Y., Yi, M., Tadros, A., Hortobagyi, G. N., Giordano, S. H., Hunt, K. K., & Mittendorf, E. A. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.4298 · Cited by 230
Platelet-to-lymphocyte ratio in advanced Cancer: Review and meta-analysis
Li, B., Zhou, P., Liu, Y., Wei, H., Yang, X., Chen, T., & Xiao, J. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.04.023 · Cited by 230
Links between Alcohol Consumption and Breast Cancer: A Look at the Evidence
Liu, Y., Nguyen, N., & Colditz, G. A. (2015) · Women's Health · doi:10.2217/whe.14.62 · Cited by 229
Iyengar, N. M., Arthur, R., Manson, J. E., Chlebowski, R. T., Kroenke, C. H., Peterson, L., Cheng, T.-Y. D., Feliciano, E. C., Lane, D., Luo, J., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5327 · Cited by 226
TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the Headlines
Shahbandi, A., Nguyen, H. D., & Jackson, J. G. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.01.007 · Cited by 226
Trastuzumab in the Treatment of Breast Cancer
Maximiano, S., Magalhães, P., Guerreiro, M. P., & Morgado, M. (2016) · BioDrugs · doi:10.1007/s40259-016-0162-9 · Cited by 223
Rothé, F., Ignatiadis, M., Chaboteaux, C., Haibe-Kains, B., Kheddoumi, N., Majjaj, S., Badran, B., Fayyad-Kazan, H., Desmedt, C., Harris, A. L., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020980 · Cited by 217
Sharma, R. (2019) · Breast Cancer · doi:10.1007/s12282-018-00941-4 · Cited by 215
Yuan, Z.-Y., Luo, R.-Z., Peng, R.-J., Wang, S.-S., & Xue, C. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s61838 · Cited by 214
Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses.
Brandes, L. J., Arron, R. J., Bogdanovic, R. P., TONG, J. J., Zaborniak, C. L., Hogg, G. R., Warrington, R. C., Fang, W., & LaBella, F. S. (1992) · PubMed · Cited by 211
Pareja, F., Geyer, F. C., Marchiò, C., Burke, K. A., Weigelt, B., & Reis-Filho, J. S. (2016) · npj Breast Cancer · doi:10.1038/npjbcancer.2016.36 · Cited by 206
Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib
Kwapisz, D. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4385-3 · Cited by 202
Plasilova, M. L., Hayse, B., Killelea, B. K., Horowitz, N. R., Chagpar, A. B., & Lannin, D. R. (2016) · Medicine · doi:10.1097/md.0000000000004614 · Cited by 201
Hormone Therapy in Breast Cancer
Drăgănescu, M., & Carmocan, C. (2017) · Chirurgia · doi:10.21614/chirurgia.112.4.413 · Cited by 199
Fang, H., Xie, J., Zhang, M., Zhao, Z., Wan, Y., & Yao, Y. (2017) · PubMed Central · Cited by 196
Vitamin D Signaling in Inflammation and Cancer: Molecular Mechanisms and Therapeutic Implications
El-Sharkawy, A., & Malki, A. (2020) · Molecules · doi:10.3390/molecules25143219 · Cited by 193
(2016) · ecancermedicalscience · doi:10.3332/ecancer.2014.464 · Cited by 192
Santonja, A., Sánchez-Muñoz, A., Lluch, A., Chica-Parrado, M. R., Albanell, J., Chacón, J. I., Antolín, S., Jerez, J. M., Haba, J. D. L., de Luque, V., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25413 · Cited by 192
Circulating circular RNA hsa_circ_0001785 acts as a diagnostic biomarker for breast cancer detection
Yin, W.-B., Yan, M.-G., Fang, X., Guo, J.-J., Xiong, W., & Zhang, R.-P. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2017.10.011 · Cited by 191
Guo, W., Lu, X., Liu, Q., Zhang, T., Li, P., Qiao, W., & Deng, M. (2019) · Cancer Medicine · doi:10.1002/cam4.2281 · Cited by 190
Biomarkers for the clinical management of breast cancer: International perspective
Patani, N., Martin, L., & Dowsett, M. (2013) · International Journal of Cancer · doi:10.1002/ijc.27997 · Cited by 189
Postmenopausal plasma sex hormone levels and breast cancer risk over 20 years of follow-up
Zhang, X., Tworoger, S. S., Eliassen, A. H., & Hankinson, S. E. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2391-z · Cited by 189
The biology of progesterone receptor in the normal mammary gland and in breast cancer
Obr, A. E., & Edwards, D. P. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.10.030 · Cited by 189
Li, Y., Yang, D., Yin, X., Zhang, X., Huang, J., Wu, Y., Wang, M., Yi, Z., Li, H., Li, H., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.18160 · Cited by 187
A stemness-related ZEB1–MSRB3 axis governs cellular pliancy and breast cancer genome stability
Morel, A.-P., Ginestier, C., Pommier, R. M., Cabaud, O., Ruiz, E., Wicinski, J., Devouassoux-Shisheboran, M., Combaret, V., Finetti, P., Chassot, C., et al. (2017) · Nature Medicine · doi:10.1038/nm.4323 · Cited by 186
Rare Mutations in XRCC2 Increase the Risk of Breast Cancer
Park, D. J., Lesueur, F., Nguyen-Dumont, T., Pertesi, M., Odefrey, F., Hammet, F., Neuhausen, S. L., John, E. M., Andrulis, I. L., Terry, M. B., et al. (2012) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2012.02.027 · Cited by 185
The Effect of Curcumin on Breast Cancer Cells
Liu, D., & Chen, Z. (2013) · Journal of Breast Cancer · doi:10.4048/jbc.2013.16.2.133 · Cited by 185
Castelló, A., Pollán, M., Buijsse, B., Ruiz, A., Casas, A. M., Baena-Cañada, J. M., Lope, V, Antolín, S., Ramos, M., Muñoz, M., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.434 · Cited by 182
NISHIMURA, R., OSAKO, T., OKUMURA, Y., HAYASHI, M., TOYOZUMI, Y., & ARIMA, N. (2010) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2010.133 · Cited by 180
Hormone replacement therapy and the risk of breast cancer
Narod, S. A. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.110 · Cited by 178
Claudin-Low Breast Cancer; Clinical & Pathological Characteristics
Dias, K., Dvorkin-Gheva, A., Hallett, R. M., Wu, Y., Hassell, J., Pond, G. R., Levine, M., Whelan, T., & Bane, A. L. (2017) · PLOS ONE · doi:10.1371/journal.pone.0168669 · Cited by 178
Prognostic significance of lymphocyte to monocyte ratio in colorectal cancer: A meta-analysis
Tan, D., Fu, Y., Tong, W., & Li, F. (2018) · International Journal of Surgery · doi:10.1016/j.ijsu.2018.05.030 · Cited by 178
Molecular stratification within triple-negative breast cancer subtypes
Wang, D., Jiang, Z., Ben‐David, Y., Woodgett, J. R., & Zacksenhaus, E. (2019) · Scientific Reports · doi:10.1038/s41598-019-55710-w · Cited by 178
Endocrine Therapy of Breast Cancer
Lumachi, F., Luisetto, G., M.M. Basso, S., Basso, U., Brunello, A., & Camozzi, V. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711794480177 · Cited by 176
Vitamin D, Calcium, and Breast Cancer Risk: A Review
Cui, Y., & Rohan, T. E. (2006) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-0075 · Cited by 176
Wetterskog, D., Lopez‐Garcia, M. A., Lambros, M. B., A'Hern, R., Geyer, F. C., Milanezi, F., Cabral, M. C., Natrajan, R., Gauthier, A., Shiu, K., et al. (2012) · The Journal of Pathology · doi:10.1002/path.2974 · Cited by 169
Global, regional, national burden of breast cancer in 185 countries: evidence from GLOBOCAN 2018
Sharma, R. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-06083-6 · Cited by 168
Reproductive factors and subtypes of breast cancer defined by hormone receptor and histology
Ursin, G., Bernstein, L., Lord, S. J., Karim, R., Deapen, D., Press, M. F., Daling, J. R., Norman, S. A., Liff, J. M., Marchbanks, P. A., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602712 · Cited by 167
PTEN Alterations and Their Role in Cancer Management: Are We Making Headway on Precision Medicine?
Fusco, N., Sajjadi, E., Venetis, K., Gaudioso, G., Lopez, G., Corti, C., Guerini Rocco, E., Criscitiello, C., Malapelle, U., & Invernizzi, M. (2020) · Genes · doi:10.3390/genes11070719 · Cited by 166
Menstrual factors in relation to breast cancer risk.
Titus-Ernstoff, L. T., Longnecker, M. P., Newcomb, P. A., Dain, B., Greenberg, E. R., Mittendorf, R. L., Stampfer, M. J., & Willett, W. C. (1998) · PubMed · Cited by 165
DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer
Kanu, N., Cerone, M. A., Goh, G., Zalmas, L.-P., Bartkova, J., Dietzen, M., McGranahan, N., Rogers, R., Law, E. K., Gromova, I., et al. (2016) · Genome Biology · doi:10.1186/s13059-016-1042-9 · Cited by 165
Prognostic value of systemic inflammatory markers and development of a nomogram in breast cancer
Cho, U., Park, H. S., Im, S. Y., Yoo, C. Y., Jung, J. H., Suh, Y. J., & Choi, H. J. (2018) · PLoS ONE · doi:10.1371/journal.pone.0200936 · Cited by 165
Huang, S. H., Waldron, J. N., Milosevic, M., Shen, X., Ringash, J., Su, J., Tong, L., Perez‐Ordonez, B., Weinreb, I., Bayley, A. J., et al. (2015) · Cancer · doi:10.1002/cncr.29100 · Cited by 161
Dietary Patterns and Breast Cancer Risk: A Systematic Review
Dandamudi, A., TOMMIE, J., Nommsen‐Rivers, L. A., & Couch, S. C. (2018) · Anticancer Research · doi:10.21873/anticanres.12586 · Cited by 160
Tumor suppressor p53 and its gain-of-function mutants in cancer
Liu, J., Zhang, C., & Feng, Z. (2014) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmt144 · Cited by 157
Effects of Alcohol on the Endocrine System
Rachdaoui, N., & Sarkar, D. K. (2013) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.05.008 · Cited by 154
Obesity in breast cancer – What is the risk factor?
James, F. R., Wootton, S. A., Jackson, A. A., Wiseman, M. J., Copson, E., & Cutress, R. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.01.057 · Cited by 152
The effect of environmental chemicals on the tumor microenvironment
Casey, S. C., Vaccari, M., Al-Mulla, F., Al-Temaimi, R., Amedei, A., Barcellos-Hoff, M. H., Brown, D. G., Chapellier, M., Christopher, J., Curran, C. S., et al. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv035 · Cited by 152
Chen, X., Wang, Q., Zhang, Y., Xie, Q., & Tan, X. (2018) · Value in Health · doi:10.1016/j.jval.2018.06.020 · Cited by 152
Gwak, J. M., Jang, M. H., Kim, D. I., Seo, A. N., & Park, S. Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125728 · Cited by 151
Neutrophils, G‐ CSF and their contribution to breast cancer metastasis
Mouchemore, K. A., Anderson, R. L., & Hamilton, J. A. (2017) · FEBS Journal · doi:10.1111/febs.14206 · Cited by 150
Candidate miRNAs in human breast cancer biomarkers: a systematic review
Adhami, M., Haghdoost, A. A., Sadeghı, B., & Afshar, R. M. (2017) · Breast Cancer · doi:10.1007/s12282-017-0814-8 · Cited by 150
Sex hormones and breast cancer risk and prognosis
Folkerd, E. J., & Dowsett, M. (2013) · The Breast · doi:10.1016/j.breast.2013.07.007 · Cited by 148
Zhang, H., Wang, X., Shen, Z., Xu, J., Qin, J., & Sun, Y. (2014) · Gastric Cancer · doi:10.1007/s10120-014-0422-7 · Cited by 147
Sobral‐Leite, M., Salomon, I., Opdam, M., Kruger, D. T., Beelen, K. J., van der Noort, V., van Vlierberghe, R. L. P., Blok, E. J., Giardiello, D., Sanders, J., et al. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1176-2 · Cited by 147
Genetic Predisposition to Breast and Ovarian Cancers: How Many and Which Genes to Test?
Angeli, D., Salvi, S., & Tedaldi, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031128 · Cited by 146
Endocrine Therapy for Early Breast Cancer: Updated Review.
Tremont, A., Lu, J., & COLE, J. T. (2017) · PubMed · Cited by 143
Newman, L. A., Reis-Filho, J. S., Morrow, M., Carey, L., & King, T. A. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-4279-0 · Cited by 142
Sex hormones in alcohol consumption: a systematic review of evidence
Erol, A., Ho, A. M., Winham, S. J., & Karpyak, V. M. (2017) · Addiction Biology · doi:10.1111/adb.12589 · Cited by 142
Preeclampsia and Breast Cancer Risk
Innes, K. E., & Byers, T. (1999) · Epidemiology · doi:10.1097/00001648-199911000-00013 · Cited by 142
Li, J., Jiang, R., Liu, W.-S., Liu, Q., Xu, M., Feng, Q.-S., Chen, L.-Z., Bei, J., Chen, M., & Zeng, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083069 · Cited by 141
Bioactivity of Turmeric-derived Curcuminoids and Related Metabolites in Breast Cancer
Wright, L. E., Frye, J. B., Gorti, B., Timmermann, B. N., & Funk, J. L. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319340013 · Cited by 140
Active cigarette smoking and risk of breast cancer
Catsburg, C., Miller, A. B., & Rohan, T. E. (2014) · International Journal of Cancer · doi:10.1002/ijc.29266 · Cited by 138
CDH1 germline mutations and hereditary lobular breast cancer
Corso, G., Intra, M., Trentin, C., Veronesi, P., & Galimberti, V. E. (2016) · Familial Cancer · doi:10.1007/s10689-016-9869-5 · Cited by 136
Vitamin D exposure and Risk of Breast Cancer: a meta-analysis
Estébanez, N., Gómez‐Acebo, I., Palazuelos, C., Llorca, J., & Dierssen‐Sotos, T. (2018) · Scientific Reports · doi:10.1038/s41598-018-27297-1 · Cited by 135
Duggan, C., Dvaladze, A., Rositch, A. F., Ginsburg, O., Yip, C., Horton, S., Camacho Rodriguez, R., Eniu, A., Mutebi, M., Bourque, J., et al. (2020) · Cancer · doi:10.1002/cncr.32891 · Cited by 134
Jiang, L., Luan, Y., Miao, X., Sun, C., Li, K., Huang, Z., Xu, D., Zhang, M., Kong, F., & Li, N. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.214 · Cited by 133
Possible mechanisms mediating an association between physical activity and breast cancer
Hoffman-Goetz, L., Apter, D., Demark-Wahnefried, W., Goran, M. I., McTiernan, A., & Reichman, M. E. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980801)83:3+<621::aid-cncr4>3.0.co;2-a · Cited by 130
Hilakivi-Clarke, L. A. (2014) · Breast Cancer Research · doi:10.1186/bcr3649 · Cited by 129
Goto, W., Kashiwagi, S., Asano, Y., Takada, K., Takahashi, K., Hatano, T., Takashima, T., Tomita, S., Motomura, H., Hirakawa, K., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-5051-9 · Cited by 128
Shah, A., Bloomquist, E. W., Tang, S. W., Fu, W., Bi, Y., Liu, Q., Yu, J., Zhao, P., Palmby, T. R., Goldberg, K. B., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2369 · Cited by 123
Cellular Pliancy and the Multistep Process of Tumorigenesis
Puisieux, A., Pommier, R. M., Morel, A., & Lavial, F. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.007 · Cited by 122
Obesity and breast cancer: A case of inflamed adipose tissue
Kolb, R., & Zhang, W. (2020) · Cancers · doi:10.3390/cancers12061686 · Cited by 119 · cited 1×
“Yet, independently to menopausal status, obese women achieve poorer clinical outcomes [92].”
BackgroundLower-Category Benign Breast Disease and the Risk of Invasive Breast Cancer
Wang, J., Costantino, J. P., Tan-Chiu, E., Wickerham, D. L., Paik, S., & Wolmark, N. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djhs105 · Cited by 119
Atezolizumab for the treatment of triple-negative breast cancer
Heimes, A.-S., & Schmidt, M. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1552255 · Cited by 117
Distinct tumor protein p53 mutants in breast cancer subgroups
Dumay, A., Feugeas, J., Wittmer, E., Lehmann‐Che, J., Bertheau, P., Espié, M., Plassa, L., Cottu, P., Marty, M., André, F., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.27767 · Cited by 116
Exposure to Endocrine Disrupting Chemicals and Risk of Breast Cancer
Eve, L., Fervers, B., Romancer, M. L., & Étienne-Selloum, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239139 · Cited by 114
Minimizing second cancer risk following radiotherapy: current perspectives
Ng, J., & Shuryak, I. (2014) · Cancer Management and Research · doi:10.2147/cmar.s47220 · Cited by 111
APOBEC3B mutagenesis in cancer
Kuong, K. J., & Loeb, L. A. (2013) · Nature Genetics · doi:10.1038/ng.2736 · Cited by 110
ZOU, Z.-Y., LIU, H.-L., Ning, N., LI, S.-Y., Du, X., & Li, R. (2016) · Oncology Letters · doi:10.3892/ol.2016.4216 · Cited by 110
Pegram, M. D., & Reese, D. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)70124-3 · Cited by 109
Zhang, M., Huang, X., Song, Y., Gao, P., Sun, J., & Wang, Z. (2017) · BioMed Research International · doi:10.1155/2017/9503025 · Cited by 109
Hereditary Breast Cancer and the BRCA1-Associated FANCJ/BACH1/BRIP1
Cantor, S. B., & Guillemette, S. (2011) · Future Oncology · doi:10.2217/fon.10.191 · Cited by 106 · cited 1×
“2 Breast cancer Fanconi anemia Involvement in the BRCA1 activity ND [48]”
BackgroundVerloop, J., van Leeuwen, F. E., Helmerhorst, T. J. M., van Boven, H. H., & Rookus, M. A. (2010) · Cancer Causes & Control · doi:10.1007/s10552-010-9526-5 · Cited by 106
Sun, L., Zhu, Y., Qian, Q., & Tang, L. (2018) · Medicine · doi:10.1097/md.0000000000011220 · Cited by 104
Cited by
Almansour, N. M. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.836417 · Cited by 397
A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer
Clusan, L., Ferrière, F., Flouriot, G., & Pakdel, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076834 · Cited by 382
Targeting Breast Cancer: An Overlook on Current Strategies
Iacopetta, D., Ceramella, J., Baldino, N., Sinicropi, M., & Catalano, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043643 · Cited by 88
Wu, H., Van Der Pol, W. J., Dubois, L. G., Morrow, C. D., & Tollefsbol, T. O. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24109015 · Cited by 27
“Introduction Breast cancer (BC) is one of the most frequently diagnosed cancers in women worldwide, and its incidence and mortality rates have been increasing over the past decades [1].”
BackgroundBreast cancer: miRNAs monitoring chemoresistance and systemic therapy
Singh, S., Saini, H., Sharma, A., Gupta, S., Huddar, V. G., & Tripathi, R. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1155254 · Cited by 25
Metadata
- Authors
- Łukasiewicz, S., Czeczelewski, M., Forma, A., Baj, J., Sitarz, R., & Stanisławek, A.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2021-08-25
- Volume
- 13
- Issue
- 17
- Pages
- 4287
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W3193347331
- Cited by
- 1,960
- References
- 272
- FWCI
- 83.89
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.